drugset / Trial / NCT03781869
Study of Anlotinib as the Maintenance Therapy for Extensive-stage Small Cell Lung Cancer
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Anlotinib has been approved as a third-line treatment for advanced non-small-cell lung cancer. A phase II clinical studies of small cell lung cancer (ALTER-1210) also showed that, compared with placebo, Anlotinib could improve the patients survival and had less toxic side effects after 2-3 line therapy. The purpose of this multicenter, randomized, prospective study is to investigate the efficacy and safety of Anlotinib as the maintenance therapy for Extensive-stage small cell lung cancer after combined with etoposide and cisplatin chemotherapy.
Timeline
- Start
- 2018-12
- Primary completion
- 2020-12
- Completion
- 2021-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Catequentinib | Small molecule | 12 mg | — |
| Background | Cisplatin | Other / unclassified | 75 mg/m2 | — |
| Background | Cisplatin | Other / unclassified | 80 mg/m2 | — |
| Background | Etoposide | Small molecule | 100 mg/m2 | — |